Transforming primary care practices into patient-centered medical homes (PCMHs) is increasingly seen as a way to enhance primary care. However, very little is known about the costs of these investment.
Transforming primary care practices into patient-centered medical homes (PCMHs) is increasingly seen as a way to enhance primary care. However, very little is known about the costs of these investment.
A report in the Journal of General Internal Medicine finds that the costs of transformation were significant and highly variable across practices. Furthermore, the ongoing costs of maintaining a medical home are substantially larger than the one-time costs of transformation, which is detrimental in making better investments in primary care practices.
Medical home initiatives encourage primary care practices to invest in new structural capabilities such as patient registries, care managers and information technology. If handled better, these transformation practices can largely improve the quality and efficiency of care, patient experience, and provider satisfaction. However, it is also important to consider the costs associated.
Grant Martsolf, PhD, MPH, RN, and fellow researchers interviewed practice representatives, identified the components of each practice’s transformation during the intervention, and calculated the corresponding costs.
Study Design and Results
For the study, the authors surveyed practice leaders across 12 practices in the Pennsylvania Chronic Care Initiative (PACCI), a statewide multi-payer medical home pilot. The objective was to identify the changes undertaken by practices due to medical home transformation. They also computed the costs of additional personnel and other investments associated with these changes.
Out of the 12 practices, 6 were family medicine or mixed specialty, 5 were internal medicine and 1 was pediatric only. Also, 7 were system-affiliated and 5 were small and independent practices.
The researchers found:
Tailored Subsidies to Avoid Financial Challenges
One-time costs included setting up patient registries, training and educating employees, and preparing internal policies and procedures. The ongoing transformation costs included new staff hiring, care management meetings, patient outreach through reminders and phone calls. The study highlighted the enormous costs undertaken for the transformation process, especially when the ongoing costs far exceeded one-time costs.
“Our findings suggest that medical home transformation can have especially challenging financial implications for small and independent practices, which incurred substantially higher per-clinician total transformation costs,” Martsolf said in a statement.
Transformation costs incurred at the system level are certainly not to be underestimated. Greater per-clinician subsidies to small and independent practices may be necessary if payers wish to avoid creating pressure for such practices to merge with larger delivery systems.
“Continuing experimentation, evaluation, and refinement of medical home interventions can help solidify the business case for making such investments in primary care practices,” Martsolf concluded.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics
March 21st 2025Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions
March 21st 2025In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.
Read More
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More